Cure8 trial brief
Noninvasive detection of intestinal fibrosis activity could help identify patients at risk of progressive scarring and surgery, and enable development or targeting of anti-fibrotic treatments for Crohn's disease.
Adults with ileal fibrostenosing Crohn's disease, patients starting biologic therapy with suspected fibrotic disease, gastroenterologists, radiologists, and researchers studying IBD fibrosis or imaging biomarkers.
This is a clinicaltrials.gov record for a single-site observational study (planned n=30) enrolling adults with ileal fibrostenosing Crohn's disease.
Participants will undergo PET/CT or PET/MRI using a fibrosis-associated protein inhibitor (FAPI) tracer to measure fibrosis activity and will be followed up to assess whether FAPI signal predicts fibrosis progression over 36 months. The study is not a treatment trial — it evaluates an imaging biomarker.
Eligibility excludes patients without small-bowel involvement, those with contraindications to imaging/contrast, impaired renal function, pregnancy, and other standard MRI/PET exclusions. Practical note: This is a recruiting, investigational imaging study at NHS Lothian (Edinburgh).
Being an observational trial, it will inform whether FAPI imaging can become a noninvasive way to detect or monitor intestinal fibrosis but does not itself test anti-fibrotic drugs.
This is an observational, biomarker-imaging study registered on clinicaltrials.gov and currently recruiting; it evaluates a PET radiotracer (FAPI) for fibrosis detection but does not test therapies. Results will require peer review and further validation before changing clinical practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Baseline MRE features may help predict which Crohn's strictures will not improve with advanced medical therapy, informing monitoring and surgical planning. Better stratification could guide decisions about earlier...
New PET tracers like FAPI could better detect fibrosis and stromal activity than standard FDG-PET, which may improve imaging of fibrostenotic Crohn's disease. For people with IBD, improved imaging might eventually help...
Risk stratification helps identify people with Crohn's who are more likely to develop strictures, fistulas, or need surgery so clinicians can monitor and treat them more aggressively early on. Objective tests like fecal...
